Eric Topol, MDs Post Two new studies zero in on the anti-inflammatory effects of the GLP-1 family of drugs, independent of weight loss, highlighting the gut-brain axis (modulating TLR response) and the gut GIP impact by Daniel Drucker and colleagues This opens up the possibility of using GLP-1 drugs in the treatment of long COVID or in conditions like schizophrenia that use the TLR pathway to activate neuroinflammation
This widespread distribution has prompted research into potential effects beyond glucose control, including neuroprotective and cognitive benefits
It is supplied by Vital Research Labs strictly as a reference compound for in-vitro laboratory investigation
Valvassori SS, Petronilho FC, Rus GZ, Steckert AV, Oliveira VB, Boeck CR, et al
The correct TRIUMPH-4 registration is NCT05931367, per Eli Lillys own press materials and ClinicalTrials.gov
GLP-1 GLP-1